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LETTER TO THE EDITOR
CHALLENGES OF A STATIN TRIAL IN OLDER
PEOPLE
To the Editor: To clarify whether starting statin treatment
in healthy older people is beneﬁcial or harmful, the
National Institute on Aging and the National Heart, Lung,
and Blood Institute multidisciplinary expert panel recom-
mends randomized controlled trials in people aged 75 years
and older.1 Although well in line with evidence-based medi-
cine, in this instance I would not be enthusiastic about the
overall beneﬁts of such trials. Remembering the Hyperten-
sion in the Very Elderly Trial (HYVET) in people aged
80 years or older,2 and frequent use of statins among older
people today, participant recruitment for a placebo-
controlled trial would be cumbersome. Furthermore, the
interpretation of results for the whole older population
would be challenging.
Contrary to the treatment of hypertension, which even in
old age seems to rapidly alleviate heart burden and reduce
incident heart failure (as demonstrated in HYVET2), such
rapid effects appear less likely with treatment of hypercholes-
terolemia in older people. Because of competing causes of
mortality, my educated guess is that no effect could be dem-
onstrated. Of course, that result would give valuable advice
against starting a statin in primary prevention after the age of
75 to 80 years, but that is already assessed critically.3
My greatest fear is that a negative result in a primary
prevention trial would falsely indicate statin treatment to be
useless in all older people. This might lead to unnecessary dis-
continuation of ongoing statin treatments solely because of
age. However, starting a statin before old age robustly pre-
vents cardiovascular events,4 and accordingly, several obser-
vational studies show that older statin users do have a better
prognosis,5 even irrespective of their functional status.6,7
Rather than putting resources on an unsecure and huge
trial in people older than 80 years, more efforts should be
made to promote starting and adhering to statin treatment
well before old age among those with cardiovascular risk.
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